Headache as a COVID-19 onset symptom or Post-COVID symptom according to the SARS-CoV-2 Variant

References

• Parra-Lucares A, Segura P, Rojas V, et al. Emergence of SARS-CoV-2 variants in the world: how could this happen? Life. 2022;12(2):194.
   PubMedGoogle Scholar
• Thye AY, Law JW, Pusparajah P, et al. Emerging SARS-CoV-2 Variants of Concern (VOCs): an impending global crisis. Biomedicines. 2021;9:1303.
   PubMed Web of Science ®Google Scholar
• Teyssou E, Delagrèverie H, Visseaux B, et al. The delta SARS-CoV-2 variant has a higher viral load than the beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients. J Infect. 2021;83:e1–e3.
   PubMed Web of Science ®Google Scholar
• Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet. 2021;398:2126–2128
   PubMed Web of Science ®Google Scholar
• Dearing L, Müller F, Sellner J. Headache with SARS-CoV-2 infection: a matter of concern. Eur J Neurol. 2021;28:3554–3555.
   PubMed Web of Science ®Google Scholar
• Moro E, Priori A, Beghi E, et al. The international European Academy of Neurology survey on neurological symptoms in patients with COVID-19 infection. Eur J Neurol. 2020;27:1727–1737.
   PubMed Web of Science ®Google Scholar
• Misra S, Kolappa K, Prasad M, et al. Frequency of neurologic manifestations in COVID-19: a systematic review and meta-analysis. Neurology. 2021;97:e2269–e2281.
   PubMed Web of Science ®Google Scholar
• Fernández-de-las-Peñas C, Navarro-Santana M, Gómez-Mayordomo V, et al. Headache as an acute and post-COVID-19 symptom in COVID-19 survivors: a meta-analysis of the current literature. Eur J Neurol. 2021;28:3820–3825.
   PubMed Web of Science ®Google Scholar
• Caronna E, Ballvé A, Llauradó A, et al. Headache: a striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution. Cephalalgia. 2020;40:1410–1421.
   PubMed Web of Science ®Google Scholar
• Porta‐Etessam J, Matías‐Guiu JA, González‐García N, et al. Spectrum of headaches associated with SARS-CoV-2 infection: study of healthcare professionals. Headache. 2020;60(8):1697–1704.
   PubMed Web of Science ®Google Scholar
• López JT, García-Azorín D, Á Á, et al. Phenotypic characterization of acute headache attributed to SARS-CoV-2: an ICHD-3 validation study on 106 hospitalized patients. Cephalalgia. 2020;40(13):1432–1442.
   PubMed Web of Science ®Google Scholar
• Á P-G, Trigo J, de Luis-García R, et al. Deep phenotyping of headache in hospitalized COVID-19 patients via principal component analysis. Front Neurol. 2020;11:583870.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Martinez A, Fanjul V, Ramos C, et al. Headache during SARS-CoV-2 infection as an early symptom associated with a more benign course of disease: a case-control study. Eur J Neurol. 2021;28:3426–3436.
   PubMed Web of Science ®Google Scholar
• Gallardo VJ, Shapiro RE, Caronna E, et al. The relationship of headache as a symptom to COVID-19 survival: a systematic review and meta-analysis of survival of 43,169 inpatients with COVID-19. Headache. 2022;62:1019–1028.
   PubMed Web of Science ®Google Scholar
• Trigo J, García-Azorín D, Planchuelo-Gómez Á, et al. Factors associated with the presence of headache in hospitalized COVID-19 patients and impact on prognosis: a retrospective cohort study. J Headache Pain. 2020;21:94.
   PubMed Web of Science ®Google Scholar
• Trigo J, García-Azorín D, Sierra-Mencía Á, et al. Cytokine and interleukin profile in patients with headache and COVID-19: a pilot, case-control, study on 104 patients. J Headache Pain. 2021;22:51.
   PubMedGoogle Scholar
• Hoang VT, Colson P, Levasseur A, et al. Clinical outcomes in patients infected with different SARS-CoV-2 variants at one hospital during three phases of the COVID-19 epidemic in Marseille, France. Infect Genet Evol. 2021;95:105092.
   PubMed Web of Science ®Google Scholar
• Park S, Lim SY, Kim JY, et al. Clinical and virological characteristics of SARS-CoV-2 B.1.617.2 (Delta) variant: a prospective cohort study. Clin Infect Dis. 2022 Apr 1;75:e27–e34.
   PubMed Web of Science ®Google Scholar
• Graham MS, Sudre CH, May A, et al. Changes in symptomatology, reinfection and transmissibility associated with SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet Public Health. 2021;6:e-335–345.
   Web of Science ®Google Scholar
• Vihta KD, Pouwels KB, Peto TEA, et al. Symptoms and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) positivity in the general population in the United Kingdom. Clin Infect Dis. 2022;75:e329–e337.
   PubMedGoogle Scholar
• Fernández-de-las-Peñas C, Cuadrado ML, Gómez-Mayordomo V, et al. Headache as a COVID-19 onset symptom and post-COVID-19 symptom in hospitalized COVID-19 survivors infected with the Wuhan, Alpha, or Delta SARS-CoV-2 variants. Headache. 2022;62:1148–1152.
   PubMed Web of Science ®Google Scholar
• Kläser K, Molteni E, Graham M, et al. COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort study. Sci Rep. 2022;12:10904.
   PubMed Web of Science ®Google Scholar
• Bie F, Yuan W, Chen Y, et al. Clinical characteristics of the delta variant of COVID-19 in Jingmen, China. Medicine (Baltimore). 2022;101:e30812.
   PubMedGoogle Scholar
• Iacobucci G. COVID-19: runny nose, headache, and fatigue are commonest symptoms of Omicron, early data show. BMJ. 2021;375:n3103.
   PubMedGoogle Scholar
• Vihta KD, Pouwels KB, Peto TE, et al. Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom. Clin Infect Dis. 2022 Aug;3:ciac613
   Google Scholar
• Kirca F, Aydoğan S, Gözalan A, et al. Comparison of clinical characteristics of wild-type SARS-CoV-2 and omicron. Rev Assoc Med Bras. 2022;68:1476–1480.
   PubMed Web of Science ®Google Scholar
• Centers for disease control and prevention, National Center for Immunization and Respiratory Diseases (NCIRD). [cited 2023 Jan 10]. Available from: https://www.cdc.gov/flu/symptoms/flu-vs-covid19.htm
   Google Scholar
• Kadirvelu B, Burcea G, Quint JK, et al. Variation in global COVID-19 symptoms by geography and by chronic disease: a global survey using the COVID-19 Symptom Mapper. EClinicalMedicine. 2022;45:101317.
   PubMedGoogle Scholar
• Long F-D-L-PC. COVID: current definition. Infection. 2022;50:285–286.
   PubMed Web of Science ®Google Scholar
• Soriano JB, Murthy S, Marshall J, et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22:e102–e107.
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society (IHS. The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38:1–211.
   PubMed Web of Science ®Google Scholar
• Caronna E, van den Hoek TC, Bolay H, et al. Headache attributed to SARS-CoV-2 infection, vaccination and the impact on primary headaches disorders of the COVID-19 pandemic: a comprehensive review. Cephalalgia. 2023;43:3331024221131337.
   Google Scholar
• Pellegrino R, Chiappini E, Licari A, et al. Prevalence and clinical presentation of long COVID in children: a systematic review. Eur J Pediatr. 2022;181:3995–4009.
   PubMed Web of Science ®Google Scholar
• Fernández-de-las-Peñas C, Notarte KI, Peligro PJ, et al. Long-COVID symptoms in individuals infected with different SARS-CoV-2 variants of concern: a systematic review of the literature. Viruses. 2022;14:2629.
   PubMed Web of Science ®Google Scholar
• Du M, Ma Y, Deng J, et al. Comparison of long COVID-19 caused by different SARS-CoV-2 strains: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022;19:16010.
   PubMedGoogle Scholar
• Magnusson K, Kristoffersen DT, Dell’Isola A, et al. Post-COVID medical complaints following infection with SARS-CoV-2 omicron vs delta variants. Nat Commun. 2022;13:7363.
   PubMed Web of Science ®Google Scholar
• Castaldo M, Waliszewska-Prosół M, Koutsokera M, et al. Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis. J Headache Pain. 2022;23:41.
   PubMed Web of Science ®Google Scholar
• Marra AR, Kobayashi T, Suzuki H, et al. The effectiveness of coronavirus disease 2019 (COVID-19) vaccine in the prevention of post-COVID-19 conditions: a systematic literature review and meta-analysis. Antimicrob Steward Healthc Epidemiol. 2022;2:e192
   PubMedGoogle Scholar
• Gao P, Liu J, Liu M. Effect of COVID-19 vaccines on reducing the risk of long COVID in the real world: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022;19:12422.
   PubMed Web of Science ®Google Scholar
• Notarte KI, Catahay JA, Velasco JV, et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. EClinicalMedicine. 2022;53:101624.
   PubMedGoogle Scholar
• García-Azorín D, Á S, Trigo J, et al. Frequency and phenotype of headache in covid-19: a study of 2194 patients. Sci Rep. 2021;11:14674.
   PubMed Web of Science ®Google Scholar
• Magdy R, Hussein M, Ragaie C, et al. Characteristics of headache attributed to COVID- 19 infection and predictors of its frequency and intensity: a cross sectional study. Cephalalgia. 2020;40:1422–1431.
   PubMed Web of Science ®Google Scholar
• Membrilla JA, de Lorenzo Í, Sastre M, et al. Headache as a cardinal symptom of coronavirus disease 2019: a cross-sectional study. Headache. 2020;60:2176–2191.
   PubMed Web of Science ®Google Scholar
• Maglietta G, Diodati F, Puntoni M, et al. Prognostic factors for post-COVID-19 syndrome: a systematic review and meta-analysis. J Clin Med. 2022;11:1541.
   PubMed Web of Science ®Google Scholar
• Thompson EJ, Williams DM, Walker AJ, et al. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun. 2022;13:3528.
   PubMed Web of Science ®Google Scholar
• Notarte KI, de Oliveira MHS, Peligro P, et al. Age, sex and previous comorbidities as risk factors not associated with SARS-CoV-2 infection for long COVID-19: a systematic review and meta-analysis. J Clin Med. 2022;11:7314.
   PubMed Web of Science ®Google Scholar
• Fernández-de-las-Peñas C, Gómez-Mayordomo V, García-Azorín D, et al. Previous history of migraine is associated with fatigue, but not headache, as long-term post-COVID symptom after SARS-CoV-2 infection: a case-control study. Front Hum Neurosci. 2021;15:678472.
   PubMed Web of Science ®Google Scholar
• Garcia-Azorin D, Layos-Romero A, Porta-Etessam J, et al. Post-COVID-19 persistent headache: a multicentric 9-months follow-up study of 905 patients. Cephalalgia. 2022;42:804–809.
   PubMed Web of Science ®Google Scholar
• Fernández-de-las-Peñas C, Gómez-Mayordomo V, Cuadrado ML, et al. The presence of headache at onset in SARS-CoV-2 infection is associated with long-term post-COVID headache and fatigue: a case-control study. Cephalalgia. 2021;41:1332–1341.
   PubMed Web of Science ®Google Scholar
• Togha M, Hashemi SM, Yamani N, et al. A review on headaches due to COVID-19 infection. Front Neurol. 2022;13:942956.
   PubMed Web of Science ®Google Scholar
• Chhabra N, Grill MF, Singh RBH. Post-COVID headache: a literature review. Curr Pain Headache Rep. 2022;26:835–842.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Kang H, Li S, et al. Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms. J Neurol. 2020;267:2179–2184.
   PubMed Web of Science ®Google Scholar
• Spudich S, Nath A. Nervous system consequences of COVID-19. Science. 2022;375:267–269.
   PubMed Web of Science ®Google Scholar
• Seehusen F, Clark JJ, Sharma P, et al. Neuroinvasion and Neurotropism by SARS-CoV-2 variants in the K18-hACE2 mouse. Viruses. 2022;14:1020.
   PubMed Web of Science ®Google Scholar
• Sigal A. Milder disease with Omicron: is it the virus or the pre-existing immunity? Nat Rev Immunol. 2022;22:69–71.
   PubMed Web of Science ®Google Scholar
• Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184:861–880.
   PubMed Web of Science ®Google Scholar
• Bolay H, Özge A, Uludüz D, et al. Are migraine patients at increased risk for symptomatic Coronavirus Disease 2019 due to shared comorbidities? Headache. 2020;60:2508–2521.
   PubMed Web of Science ®Google Scholar
• Charfeddine S, Ibn Hadj Amor H, Jdidi J, et al. Long COVID 19 syndrome: is it related to microcirculation and endothelial dysfunction? Insights from TUN-EndCOV study. Front Cardiovasc Med. 2022;8:745758.
   Web of Science ®Google Scholar
• Paolucci M, Altamura C, Vernieri F. The role of endothelial dysfunction in the pathophysiology and cerebrovascular effects of migraine: a narrative review. J Clin Neurol. 2021;17:164–175.
   PubMed Web of Science ®Google Scholar
• Mulchandani R, Lyngdoh T, Kakkar AK. Deciphering the COVID-19 cytokine storm: systematic review and meta-analysis. Eur J Clin Invest. 2021;51:e13429.
   PubMed Web of Science ®Google Scholar
• Afrin LB, Weinstock LB, Molderings GJ. COVID-19 hyperinflammation and post-COVID-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020;100:327–332.
   PubMed Web of Science ®Google Scholar
• Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: a systematic review and meta-analysis. Rev Med Virol. 2020;30:1–9.
   PubMed Web of Science ®Google Scholar
• Sharifkashani S, Bafrani MA, Khaboushan AS, et al. Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: potential therapeutic targeting. Eur J Pharmacol. 2020;884:173455.
   PubMed Web of Science ®Google Scholar
• Conti P, D’Ovidio C, Conti C, et al. Progression in migraine: role of mast cells and pro-inflammatory and anti-inflammatory cytokines. Eur J Pharmacol. 2019;844:87–94.
   PubMed Web of Science ®Google Scholar
• Bougea A, Spantideas N, Galanis P, et al. Salivary inflammatory markers in tension type headache and migraine: the SalHead cohort study. Neurol Sci. 2020;41:877–884.
   PubMed Web of Science ®Google Scholar
• Gales BJ, Bailey EK, Reed AN, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines. Ann Pharmacother. 2010;44:360–366.
   PubMed Web of Science ®Google Scholar
• Straburzyński M, Kuca-Warnawin E, Waliszewska-Prosół M. COVID-19-related headache and innate immune response - a narrative review. Neurol Neurochir Pol. 2022 Jun 27. DOI:10.5603/PJNNS.a2022.0049.
   PubMed Web of Science ®Google Scholar
• Saunders C, Sperling S, Bendstrup E. A new paradigm is needed to explain long COVID. Lancet Respir Med. 2023 Jan 5;11:e12–e13.
   PubMed Web of Science ®Google Scholar
• Balasubramanian B, VasundharaaS N, George N, et al. A bio-psychosocial framework for chronic daily headaches: a mixed methods study. J Patient Exp. 2021;8:23743735211049672.
   Google Scholar
• Bilgin A, Kesik G, Ozdemir L. Biopsychosocial factors predicting pain among individuals experiencing the novel coronavirus disease (COVID-19). Pain Manag Nurs. 2022;23:79–86.
   PubMed Web of Science ®Google Scholar